Related Experiment Video
Updated: Jul 30, 2026
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple
Thomas F Scott1, Carol J Schramke, Gary Cutter
1Drexel University College of Medicine, Department of Neurology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA. tscott@wpahs.org
Background:
Risk factors for short-term progression in early relapsing remitting MS have been identified recently. Previously we determined potential risk factors for rapid progression of early relapsing remitting MS and identified three groups of high-risk patients. These non-mutually exclusive groups of patients were drawn from a consecutively studied sample of 98 patients with newly diagnosed MS. High-risk patients had a history of either poor recovery from initial attacks, more than two attacks in the first two years of disease, or a combination of at least four other risk factors.
Objective:
To determine differences in sample sizes required to show a meaningful treatment effect when using a high-risk sample versus a random sample of patients.
Methods:
Power analyses were used to calculate the different sample sizes needed for hypothetical treatment trials.
Results:
We found that substantially smaller numbers of patients should be needed to show a significant treatment effect by employing these high-risk groups of patients as compared to a random population of MS patients (e.g., 58% reduction in sample size in one model).
Conclusion:
The use of patients at higher risk of progression to perform drug treatment trials can be considered as a means to reduce the number of patients needed to show a significant treatment effect for patients with very early MS.
Insights
Utilizing high-risk patient groups in early multiple sclerosis (MS) clinical trials significantly reduces the number of participants needed. This approach streamlines drug development for very early MS by focusing on patients with a higher likelihood of disease progression.
Area of Science:
- Neurology
- Clinical Trials
- Multiple Sclerosis Research
Background:
- Recent identification of risk factors for short-term progression in early relapsing-remitting MS.
- Previously identified three high-risk patient groups based on initial attack recovery, attack frequency, and other risk factors.
- Study sample comprised 98 consecutively diagnosed MS patients.
Purpose of the Study:
- To compare sample sizes required for detecting meaningful treatment effects in early MS trials.
- To evaluate the efficiency of using high-risk patient cohorts versus random samples.
Main Methods:
- Power analyses were conducted to calculate necessary sample sizes for hypothetical treatment trials.
- Comparison of sample size requirements between high-risk and random patient samples.
Main Results:
- Substantially smaller sample sizes are needed when using high-risk MS patient groups.
- Potential for a 58% reduction in sample size in one model by employing high-risk cohorts.
- Demonstrated efficiency of high-risk sampling for detecting treatment effects.
Conclusions:
- Employing high-risk patients in early MS drug trials can reduce participant numbers.
- This strategy offers a more efficient approach to demonstrating treatment efficacy in very early MS.
- Consideration of high-risk cohorts can accelerate therapeutic development for MS.
More Related Videos
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
08:33A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
